Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide : A Study on Behalf of GETH-TC
Fonseca-Santos, Marta (Hospital Universitario de Salamanca)
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón)
López-Godino, Oriana (Hospital General Universitario Morales Meseguer (Múrcia))
Herruzo-Delgado, Beatriz (Hospital Regional Universitario de Málaga)
Bermudez, Maria Aranzazu (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Garcia Cadenas, Irene (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Huguet, María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ferra-Coll, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Esquirol, Albert (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Cortés-Rodriguez, María (Universidad de Salamanca)
Yáñez, Lucrecia (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Pascual-Cascon, Maria Jesus (Hospital Universitario Regional de Málaga (Andalusia))
Heras, Inmaculada (Hospital General Universitario Morales Meseguer (Múrcia))
Kwon, Mi (Hospital General Universitario Gregorio Marañón)
Lopez-Corral, Lucía (Hospital Universitario de Salamanca)

Date:	2024
Abstract:	Background. Chronic graft-versus-host disease (cGVHD) is a cause of late morbidity and nonrelapse mortality (NRM) after allogenic hematopoietic stem cell transplantation (allo-HSCT). Although studies evaluating haploidentical allo-HSCT (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) demonstrate lower cGVHD rates, comprehensive data describing the clinical profile, risk factors, or outcomes of cGVHD within this platform are scarce. Methods. We conducted a retrospective multicenter analysis of 389 consecutive patients who underwent haplo-HSCT PTCy in 7 transplant centers of the Spanish Group Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) between 2008 and 2020 describing incidence, clinical profile, risk factors, and cGVHD outcomes. Results. Ninety-five patients of 389 developed cGVHD. Our data revealed that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis and that the strongest predictor for cGVHD was previous acute GVHD (P = 0. 031). Also, recipient age ≥60 y (P = 0. 044) was protective against cGVHD. Moreover, patients with moderate cGVHD had longer event-free survival at 3 y than other patients (P = 0. 016) and a lower relapse rate at 3 y (P = 0. 036). Conclusions. Our results support the fact that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis. In this series, patients who develop moderate cGVHD after haplo-HSCT PTCy had a higher overall survival and event-free survival, and lower relapse, suggesting higher graft-versus-leukemia effect. Although this is the largest series focused on characterizing cGVHD in haplo-HSCT PTCy, further prospective studies are needed to confirm the findings.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Transplantation, Vol. 108 Núm. 10 (October 2024) , p. 2134-2143, ISSN 1534-6080

DOI: 10.1097/TP.0000000000005034

10 p, 894.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Research articles
Articles > Published articles